Cancer serum index: a useful nonspecific test as a parameter in multimodality screening and assessment of patients with cancer of the prostate.
Publication/Presentation Date
1-1-1981
Abstract
A satisfactory, simple test for screening and monitoring of patients with prostatic cancer is still being sought. We suggest the use of a nonspecific test in combination with other tests. The ratio of two serum proteins (alpha 1 acid glycoprotein [AGP] and prealbumin [PAB]), may be useful markers for a cancer serum index (CSI). By separating serum components by gradient polyacrylamide gel electrophoresis, staining and quantitating these proteins by scanning densitometry, and dividing the area of AGP by that of PAB, indices can be obtained. In a test of sera from 450 patients with prostatic cancer, other urologic problems, and normal controls, CSIs of 360 sera presently decoded were found to be: (Formula: see text). The CSI should prove highly valuable when used in combination with selected prostatic cancer tests.
Volume
2
Issue
2
First Page
207
Last Page
217
ISSN
0270-4137
Published In/Presented At
Kundin, W. D., Mechali, P., Hollinshead, A. C., Bensimon, H., & Miller, H. (1981). Cancer serum index: a useful nonspecific test as a parameter in multimodality screening and assessment of patients with cancer of the prostate. The Prostate, 2(2), 207–217. https://doi.org/10.1002/pros.2990020209
Disciplines
Medicine and Health Sciences
PubMedID
6170965
Department(s)
Department of Surgery
Document Type
Article